#Vienna #Austria #PF Products #AVVie GmbH #AngelValve

P&F Products & Features GmbH Expands Portfolio Through Acquisition of AVVie GmbH

On August 6, 2026, P&F Products & Features GmbH (P&F) made a significant move in the healthcare technology sector by announcing its acquisition of AVVie GmbH. Founded by renowned cardiac surgeon Professor Werner Mohler, AVVie has developed a cutting-edge augmentation system known as AngelValve™, designed to address complex heart valve diseases, particularly mitral regurgitation.

Addressing a Critical Healthcare Need

Mitral regurgitation affects more than 13 million people across Europe and the United States. This serious condition occurs when blood leaks backward into the left atrium of the heart, leading to major health complications. Despite the severity of the disease, currently, only around 5% of patients with moderate to severe mitral regurgitation receive treatment. By acquiring AVVie, P&F aims to close this treatment gap, improving the quality of life for millions.

The acquisition not only enhances P&F’s portfolio in structural heart disease but also reinforces its long-standing commitment to innovation in transcatheter therapies for next-generation heart valve treatments. The AngelValve™ system offers a novel catheter-based solution to meet urgent needs in the treatment landscape of mitral valve diseases, particularly for patients with limited or no treatment options.

Merging Expertise for Innovation

The combination of AVVie's R&D infrastructure and intellectual property with P&F's global resources in product development, clinical and regulatory affairs, and commercialization positions the newly formed entity to accelerate innovation and shorten product development timelines. Dr. Katharina Kiss, CEO of P&F, emphasized that this acquisition reflects the company’s dedication to delivering groundbreaking therapies for structural heart conditions. “Bringing together AVVie’s technical excellence with our clinical study and regulatory know-how presents a fantastic opportunity to further develop the AngelValve™ platform,” she stated.

Siegfried Einhellig, P&F’s COO and President, echoed this sentiment, highlighting how the collaboration marries superb engineering talent with proven development capabilities. This synergy is expected to lead to breakthroughs that can transform patient care in cardiology.

A Commitment to Future Developments

The financial terms of this acquisition have not been disclosed; however, P&F has made it clear that its mission is to enhance therapeutic interventions for those affected by structural heart diseases. The company, headquartered in Vienna, Austria, boasts over 25 years of experience in developing innovative cardiovascular solutions and operates in around 70 countries, with manufacturing facilities in Europe, Asia, and Brazil.

With this strategic acquisition, P&F Products & Features GmbH is taking significant steps to strengthen its market position and further its mission of innovating heart therapies worldwide. As the company integrates AVVie’s expertise and technologies, stakeholders in the medical community will be closely observing the developments that emerge from this union, anticipating significant contributions to heart health treatments. For more information, visit productsandfeatures.com.